Contemporary Lipid Assessment: Why Cholesterol Alone May Not Tell the Full Story

Traditional cholesterol testing remains important, but modern cardiovascular prevention has moved beyond simply asking whether “cholesterol is high.” Current international guidance increasingly recognises that cardiovascular risk is influenced not only by LDL-cholesterol, but also by the number of atherogenic particles, inherited lipid markers, inflammation, diabetes risk, blood pressure, ECG findings and the wider clinical picture. (European Society of Cardiology)

At Hourglass Wellbeing, our approach is to interpret lipid results in context — combining advanced blood testing, cardiovascular risk assessment and consultant-led guidance where appropriate.

Why a standard lipid profile may not be enough

A standard lipid profile usually includes total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides. These are useful markers, but they do not always capture the full risk picture.

One key limitation is that LDL-cholesterol measures the amount of cholesterol carried inside LDL particles, not the number of atherogenic particles circulating in the blood. In some people, particularly those with insulin resistance, type 2 diabetes, raised triglycerides, metabolic syndrome or obesity, LDL-cholesterol may appear acceptable while the number of atherogenic particles remains high.

This is where Apolipoprotein B, or ApoB, can be helpful. ApoB reflects the number of atherogenic lipoprotein particles, including LDL, VLDL and remnant particles. Evidence from major analyses suggests ApoB can provide more accurate risk information than LDL-cholesterol alone, particularly when results are discordant. (PMC)

Lipoprotein(a): the inherited risk marker many people have never had checked

Lipoprotein(a), or Lp(a), is a largely inherited lipid particle associated with a higher risk of atherosclerotic cardiovascular disease and aortic valve stenosis. It is not measured in a routine cholesterol test.

The European Atherosclerosis Society and ESC/EAS guidance support measuring Lp(a) at least once in adulthood, particularly to identify people with substantially elevated inherited risk that may otherwise be missed. (EAS)

This is especially relevant for people with:

• a family history of premature heart disease

• unexpectedly high cholesterol

• cardiovascular disease despite “reasonable” cholesterol levels

• suspected familial hypercholesterolaemia

• unexplained early vascular disease

• aortic valve disease

LDL subfractions and particle quality

Not all LDL patterns are the same. LDL subfraction analysis may provide additional insight into particle size and distribution, particularly in people with metabolic risk, raised triglycerides or insulin resistance. While LDL-cholesterol remains a major treatment target, more detailed lipid phenotyping can help refine the overall risk discussion when interpreted carefully alongside ApoB, Lp(a), metabolic markers and clinical risk.

A more complete cardiovascular risk picture

Advanced lipid testing is most useful when it is not interpreted in isolation. A “premium” cardiovascular risk assessment can combine lipid science with broader clinical context, including:

• full lipid profile

• ApoB

• ApoA1

• Lipoprotein(a)

• LDL subfractions

• full blood count

• kidney, liver and thyroid function

• iron studies

• calcium levels

• CRP as an inflammatory marker

• HbA1c for diabetes risk

• ECG

• consultant interpretation and personalised guidance

This approach aligns with modern prevention guidance, which emphasises personalised risk assessment, risk modifiers and shared decision-making rather than relying on one cholesterol number alone. (EAS)

Who may benefit from advanced lipid assessment?

Advanced lipid assessment may be particularly useful for people with:

• family history of premature heart attack or stroke

• borderline or unexplained cholesterol results

• high cholesterol despite a healthy lifestyle

• diabetes, pre-diabetes or metabolic syndrome

• raised triglycerides

• hypertension

• previous cardiovascular disease

• inflammatory conditions

• South Asian, Middle Eastern or other higher-risk ethnic backgrounds

• uncertainty about whether lipid-lowering treatment is needed

Beyond numbers: interpretation matters

The value of advanced testing lies not simply in producing more results, but in interpreting them properly. A mildly abnormal result may be very important in one patient and less concerning in another. Conversely, a standard cholesterol profile that looks “acceptable” may underestimate risk if ApoB or Lp(a) is high.

At Hourglass Wellbeing, advanced lipid assessment can be combined with cardiovascular risk review, ECG and consultant-led interpretation to provide a clearer, evidence-based understanding of your personal risk.

Patients can book online via our cardiovascular risk assessment pages or contact the clinic by email to discuss the most appropriate assessment.

References

1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227–3337.

2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020;41:111–188.

3. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: EAS consensus statement. European Heart Journal. 2022;43:3925–3946.

4. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease. JAMA Cardiology. 2019;4:1287–1295.

5. Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs LDL-cholesterol and non-HDL-cholesterol as the primary measure of atherogenic lipid risk. Journal of the American Heart Association. 2022;11:e025858.

6. European Society of Cardiology/European Atherosclerosis Society. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal / Atherosclerosis. 2025.